Bosentan for high-risk outpatients with COVID-19 infection: a randomized, double blind, placebo-controlled trial

Shaahin Shahbazi; Zahra Vahdat Shariatpanahi; Erfan Shahbazi

doi:10.1016/j.eclinm.2023.102117

Bosentan for high-risk outpatients with COVID-19 infection: a randomized, double blind, placebo-controlled trial

EClinicalMedicine. 2023 Jul 27:62:102117. doi: 10.1016/j.eclinm.2023.102117. eCollection 2023 Aug.

Authors

Shaahin Shahbazi¹, Zahra Vahdat Shariatpanahi², Erfan Shahbazi³

Affiliations

¹ Department of Internal Medicine, Faculty of Medicine, Ilam University of Medical Sciences, Iran.
² Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Iran.
³ School of Medicine, Tehran University of Medical Sciences, Iran.

Abstract

Background: The endothelium is supposedly activated and damaged in COVID-19 because of endothelin-1 over-secretion. This study evaluates the effect of bosentan as an endothelin receptor blocker on the progression of disease in high-risk outpatients with COVID-19 infection.

Methods: From 15 December 2021 to 15 May 2022, high-risk outpatients were randomly assigned to receive bosentan, 62.5 mg or placebo twice daily from enrollment for 30 days. Both groups received standard medical treatment too. On day 30 of the trial, the patients underwent complete doppler ultrasound of the lower extremities to detect asymptomatic thromboembolic events. The primary outcome in this study was hospitalization or death from any cause within the first 15 days. Secondary outcomes included thromboembolic events, hospital-free days and death from any cause within 30 days after randomization (IRCT.ir, IRCT20211203053263N1).

Findings: Basal characteristics of the two groups were similar. Primary outcomes occurred in 3 (2.3%) of the 129 patients in the bosentan group versus 15 (11.5%) of the 130 patients in the placebo group [risk difference: -9.2% (95% CI: -15.3 to -3.1), P = 0.006]. Median hospital-free days was significantly higher in the bosentan group (P = 0.004). A total of three deaths occurred and all were in the control group. Bosentan was associated with a nonsignificant reduction in mortality compared with placebo (P = 0.24). Thromboembolic events occurred in one (1%) of 97 patients in the bosentan group versus nine (8.7%) of 104 patients in the placebo group within 30 days after randomization [risk difference: -8.3% (95% CI: -14.4 to -2.2), P = 0.008].

Interpretation: Early administration of bosentan may prevent disease progression and thromboembolic events in high-risk outpatients with COVID-19.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Keywords: Adverse event; Doppler; Hospitalization; Mortality; Thromboembolic events.